Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials

Cancer

Volumn 119, Issue 20, 2013, Pages 3610-3618

  Schweizer, Michael T ^a   Huang, Peng ^a   Kattan, Michael W ^b   Kibel, Adam S ^c   De Wit, Ronald ^d   Sternberg, Cora N ^e   Epstein, Jonathan I ^a,f,g   Eisenberger, Mario A ^a,g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

adjuvant therapy; docetaxel; leuprolide; prostate cancer; testosterone recovery

Indexed keywords

DOCETAXEL; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CONSENSUS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEBRILE NEUTROPENIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NOMOGRAM; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADJUVANT THERAPY; DOCETAXEL; LEUPROLIDE; PROSTATE CANCER; TESTOSTERONE RECOVERY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 84885172236     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28270     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910-914. (Pubitemid 39096421)
3. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA,. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006; 176: 564-568. (Pubitemid 43927886)
4. Pound CR, Partin AW, Epstein JI, Walsh PC,. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24: 395-406. (Pubitemid 27169264)
5. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17: 1499-1507. (Pubitemid 29220858)
6. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM,. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994; 152 (5 pt 2): 1850-1857. (Pubitemid 24322643)
7. Lieskovsky G, Bochner BH, Skinner EC, et al. Evaluation of 20-year experience with radical retropubic prostatectomy for adenocarcinoma of the prostate. J Urol. 1999; 161: A329.
8. Epstein JI, Partin AW, Sauvageot J, Walsh PC,. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996; 20: 286-292. (Pubitemid 26071509)
9. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290. (Pubitemid 40470408)
10. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591. (Pubitemid 351264352)
11. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103-106.
12. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
13. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978. (Pubitemid 46606211)
14. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003; 21: 1904-1911. (Pubitemid 46606377)
15. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827. (Pubitemid 39079668)
16. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011; 29: 2040-2045.
17. Bastide C, Rossi D, Lechevallier E, et al. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int. 2012; 109: 525-530; discussion 531-522.
18. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D,. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 1781-1788.
19. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP,. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010; 105: 1074-1081.
20. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. (Pubitemid 39315317)
21. Kattan MW, Eastham J,. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer. 2003; 1: 221-226. (Pubitemid 37021458)
22. Kattan MW,. Evaluating a new marker's predictive contribution. Clin Cancer Res. 2004; 10: 822-824. (Pubitemid 38198879)
23. Rosenbaum E, Kibel A, Roth BJ, et al. Adjuvant weekly docetaxel (D) for high-risk prostate cancer (PC) patients (pts) after radical prostatectomy (RP): preliminary data of a multicenter pilot trial. J Clin Oncol. 2004; 23: 417.
24. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006; 296: 2329-2335. (Pubitemid 44749360)
25. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366: 572-578. (Pubitemid 41140332)
26. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009; 27: 2924-2930.
27. Gulley JL, Aragon-Ching JB, Steinberg SM, et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2008; 180: 1432-1437; discussion 1437.
28. Tunn UW, Canepa G, Kochanowsky A, Kienle E,. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2012; 15: 296-302.
29. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R,. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol. 2008; 180: 1438-1443; discussion 1443-1434.
30. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439. (Pubitemid 41124175)
31. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012; 109: 32-39.
32. Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA,. Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer. 2012; 118: 1533-1542.
33. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523. (Pubitemid 36132976)
34. Cuppone F, Bria E, Giannarelli D, et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer. 2010; 10: 675.
35. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD,. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006; (4): CD006019.
36. Roach M 3rd, Thomas K,. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012; 2012: 221-229.
37. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 1243-1252. (Pubitemid 32727802)
38. Cancer and Leukemia Group B. Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients with High-Risk Localized Prostate Cancer [Identifier: NCT00430183]. Bethesda, MD: National Library of Medicine; 2000. clinicaltrials.gov/show/NCT00430183 NLM. Accessed March 8, 2013.
39. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013-1021. (Pubitemid 27106285)
40. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012; 380: 2018-2027.
41. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181: 956-962.